ARGX Jan 2025 360.000 call
| Previous close | 90.80 |
| Open | 90.80 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 360.00 |
| Expiry date | 2025-01-17 |
| Day's range | 90.80 - 90.80 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Hidden Gems: Three Stocks Estimated Below Market Value in June 2024
As global markets exhibit mixed signals with some indices reaching all-time highs and others showing modest gains amidst economic uncertainties, investors continue to search for value in a complex landscape. In this context, identifying stocks that are potentially undervalued becomes a strategic approach to uncover hidden gems in the market.
GlobeNewswireargenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company
ZacksArgenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
